Welcome to the era of mindful medicine.
The Latest From The Lab:
Distinguished Neuroscience Expert
Magali Haas, MD/PhD, Joins Psilera
as Chief Medical Officer
Read the full press release here!
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds. Several more patents expected by 1H 2024.
-
The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small molecule drug discovery is done, giving rise to more patient-centric therapy options for those suffering from neurological conditions.
Based on the current pipeline, our focus is on hard-to-treat disorders, many of which have no currently available treatments, such as Frontotemporal Dementia (FTD).
UPCOMING EVENTS
UPCOMING EVENTS
March 10 - 11
Miami, FL
April 8
San Diego, CA
February 28 - 29
Boston, MA
LSX Investival Showcase USA
The Business Development team will be hitting the beautiful beaches of Miami for the LSX Investival Showcase. This will be the first year the USA will host this unique event where life-science innovators and game-changing capital and partnership opportunities unite. Co-Founder Chris Witowski, PhD, EVP of Corporate Dev. Scott Rairigh and Marketing Director Katie DeMarsh will be available to connect if you would like to learn more!
Husch Blackwell and Aquillius VC Event
Co-Founder and CSO Dr Jackie von Salm will be making a virtual appearance at the Husch Blackwell and Aquillius VC event in San Diego. She will be speaking on the panel “ What Pharma Wants: Positioning Psychedelic Assets for Partnership & Acquisition” along side Adam Klein, Ph.D., (Senior Scientist, Gilgamesh Pharmaceuticals), Odette Hauke, (Regulatory Affairs Consultant at Odette Alina LLC, formerly of ataiBeckley) and Kimberly Chew (Senior Counsel & Co-Leader, Psychedelics and Emerging Therapies Practice, Husch Blackwell LLP and moderator.) Whether you’re an entrepreneur, scientist, investor, or industry executive, this session will provide actionable insights and a rare behind-the-scenes look at how deals get done in this dynamic field.
Neuroscience Innovation
Pharma Partnering Summit
In the spring, Jackie von Salm, PhD will be speaking at the Neuroscience Innovation Pharma Partnering Summit in Boston. Focused on accelerating collaboration and partnership across neurology and psychiatry, the Summit will allow key opinion leaders in the CNS space the opportunity to forge new connections. If you will be in Boston for the event and would like to connect, please message us at info@psilera.com.